Literature DB >> 13723621

Investigations of the amnesic properties of scopolamine and related compounds.

F R DOMER, F W SCHUELER.   

Abstract

Entities:  

Keywords:  AMNESIA/experimental; PARASYMPATHOLYTICS/pharmacology; SCOPOLAMINE/pharmacology

Mesh:

Substances:

Year:  1960        PMID: 13723621

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


× No keyword cloud information.
  8 in total

1.  EFFECTS OF BENACTYZINE AND ADIPHENINE ON INSTRUMENTAL AVOIDANCE CONDITIONING IN A SHUTTLE-BOX.

Authors:  G BIGNAMI
Journal:  Psychopharmacologia       Date:  1964-03-11

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Modification of conditional behavior by prior experience.

Authors:  C A Berry; L G Stark
Journal:  Psychopharmacologia       Date:  1965-05-21

4.  An examination of central actions characteristic of scopolamine: comparison of central and peripheral activity in scopolamine, atropine and some synthetic basic esters.

Authors:  M W Aparkes
Journal:  Psychopharmacologia       Date:  1965-01-14

5.  Modification of novelty preferences in rats by current and prior treatment with scopolamine and methylscopolamine.

Authors:  R J Horsburgh; R N Hughes
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  THE INFLUENCE OF CENTRALLY ACTING CHOLINOLYTIC DRUGS ON BRAIN ACETYLCHOLINE LEVELS.

Authors:  N J GIARMAN; G PEPEU
Journal:  Br J Pharmacol Chemother       Date:  1964-08

7.  Effects of scopolamine, pilocarpine, and oxotremorine on the exploratory behavior of two psychogenetically selected lines of rats in a complex maze.

Authors:  J R Martin; D H Overstreet; P Driscoll; K Bättig
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  New insights into huperzine A for the treatment of Alzheimer's disease.

Authors:  Hai-Yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2012-09-03       Impact factor: 6.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.